Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis

Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line

“…This phenomenon was also observed in esophageal adenocarcinoma and squamous carcinoma cell line OE33 and KYSE 110 [ 21 ], respectively, and in three renal cell carcinoma cell lines (KTCL26, SKRC18 and SKRC39) [ 16 ]. Interestingly, RPRM is located at chromosome 2q23.3, a locus that often has allelic imbalance in BC [ 27 ]; nevertheless, we observed that loss or repression of mRNA expression was restored by 5′Aza-dC treatment, concluding that there is probably no allelic imbalance of 2q23 involved in loss of RPRM mRNA expression in these two cell lines.…”

Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line

“…This phenomenon was also observed in esophageal adenocarcinoma and squamous carcinoma cell line OE33 and KYSE 110 [ 21 ], respectively, and in three renal cell carcinoma cell lines (KTCL26, SKRC18 and SKRC39) [ 16 ]. Interestingly, RPRM is located at chromosome 2q23.3, a locus that often has allelic imbalance in BC [ 27 ]; nevertheless, we observed that loss or repression of mRNA expression was restored by 5′Aza-dC treatment, concluding that there is probably no allelic imbalance of 2q23 involved in loss of RPRM mRNA expression in these two cell lines.…”

Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing

“…Recent studies have shown chromosome 2 microdeletions in several cancers, such as neuroblastoma and breast, lung, and cervical cancers. [26][27][28][29] Strikingly, most of the deletions detected in this patient sample are in genes located in Chr2 q37.3 (Table 1, Figure 2A), an area that harbors many genes involved in skeletal and neuronal development. Although the 2q37.3 deletion was a somatic event for our patient, it is interesting to mention that the 2q37 deletion syndrome consists of a germline loss of Chr2 (q37.1, q37.2, q37.3).…”

Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk

“…In 2002, it was announced that a candidate TSG on the X chromosome was identified using chromosome transfer experiments [30]. Additionally, deletions at Xq25 have been reported to be associated with ovarian cancer [20], and Piao et al found a high frequency of LOH on chromosome arm Xq in breast cancer cells [31]. Piao et al also identified that LOH of DXS8098 at Xq25 is associated with a larger tumour size (>3 cm), a higher histologic grade, and axillary lymph node metastasis, suggesting that there could be one or more TSGs in this region [21].…”

Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line

“…This phenomenon was also observed in esophageal adenocarcinoma and squamous carcinoma cell line OE33 and KYSE 110 [ 21 ], respectively, and in three renal cell carcinoma cell lines (KTCL26, SKRC18 and SKRC39) [ 16 ]. Interestingly, RPRM is located at chromosome 2q23.3, a locus that often has allelic imbalance in BC [ 27 ]; nevertheless, we observed that loss or repression of mRNA expression was restored by 5′Aza-dC treatment, concluding that there is probably no allelic imbalance of 2q23 involved in loss of RPRM mRNA expression in these two cell lines.…”

Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing

“…Recent studies have shown chromosome 2 microdeletions in several cancers, such as neuroblastoma and breast, lung, and cervical cancers. [26][27][28][29] Strikingly, most of the deletions detected in this patient sample are in genes located in Chr2 q37.3 (Table 1, Figure 2A), an area that harbors many genes involved in skeletal and neuronal development. Although the 2q37.3 deletion was a somatic event for our patient, it is interesting to mention that the 2q37 deletion syndrome consists of a germline loss of Chr2 (q37.1, q37.2, q37.3).…”

Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk

“…In 2002, it was announced that a candidate TSG on the X chromosome was identified using chromosome transfer experiments [30]. Additionally, deletions at Xq25 have been reported to be associated with ovarian cancer [20], and Piao et al found a high frequency of LOH on chromosome arm Xq in breast cancer cells [31]. Piao et al also identified that LOH of DXS8098 at Xq25 is associated with a larger tumour size (>3 cm), a higher histologic grade, and axillary lymph node metastasis, suggesting that there could be one or more TSGs in this region [21].…”

Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line

“…This phenomenon was also observed in esophageal adenocarcinoma and squamous carcinoma cell line OE33 and KYSE 110 [ 21 ], respectively, and in three renal cell carcinoma cell lines (KTCL26, SKRC18 and SKRC39) [ 16 ]. Interestingly, RPRM is located at chromosome 2q23.3, a locus that often has allelic imbalance in BC [ 27 ]; nevertheless, we observed that loss or repression of mRNA expression was restored by 5′Aza-dC treatment, concluding that there is probably no allelic imbalance of 2q23 involved in loss of RPRM mRNA expression in these two cell lines.…”

Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing

“…Recent studies have shown chromosome 2 microdeletions in several cancers, such as neuroblastoma and breast, lung, and cervical cancers. [26][27][28][29] Strikingly, most of the deletions detected in this patient sample are in genes located in Chr2 q37.3 (Table 1, Figure 2A), an area that harbors many genes involved in skeletal and neuronal development. Although the 2q37.3 deletion was a somatic event for our patient, it is interesting to mention that the 2q37 deletion syndrome consists of a germline loss of Chr2 (q37.1, q37.2, q37.3).…”

Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk

“…In 2002, it was announced that a candidate TSG on the X chromosome was identified using chromosome transfer experiments [30]. Additionally, deletions at Xq25 have been reported to be associated with ovarian cancer [20], and Piao et al found a high frequency of LOH on chromosome arm Xq in breast cancer cells [31]. Piao et al also identified that LOH of DXS8098 at Xq25 is associated with a larger tumour size (>3 cm), a higher histologic grade, and axillary lymph node metastasis, suggesting that there could be one or more TSGs in this region [21].…”